Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference
About
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in
Alkermes Contact:
Investor Relations
+1 781 873 2402

View original content:https://www.prnewswire.co.uk/news-releases/alkermes-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302341500.html
